On Friday 06/28/2024 the closing price of the Quest Diagnostics Inc. share was $137.33 on BTT.
Compared to the opening price on Friday 06/28/2024 on BTT of $138.16, this is a drop of 0.60%.
Quest Diagnostics Inc.'s market capitalization is $15.43 B by 111.09 M shares outstanding.
Is Quest Diagnostics stock a Buy, Sell or Hold?
Quest Diagnostics stock has received a consensus rating of hold. The average rating score is and is based on 6 buy ratings, 24 hold ratings, and 1 sell ratings.What was the 52-week low for Quest Diagnostics stock?
The low in the last 52 weeks of Quest Diagnostics stock was 119.61. According to the current price, Quest Diagnostics is 114.44% away from the 52-week low.What was the 52-week high for Quest Diagnostics stock?
The high in the last 52 weeks of Quest Diagnostics stock was 145.61. According to the current price, Quest Diagnostics is 94.00% away from the 52-week high.What are analysts forecasts for Quest Diagnostics stock?
The 31 analysts offering price forecasts for Quest Diagnostics have a median target of 147.06, with a high estimate of 165.00 and a low estimate of 125.00. The median estimate represents a 93.07 difference from the last price of 136.88.Quest Diagnostics Stock Snapshot
136.76
Bid
100.00
Bid Size
136.90
Ask
100.00
Ask Size
6/28/2024
Date
3:59 PM
Time
29,995.00
Volume
137.33
Prev. Close
138.16
Open
111.09 M
Number of Shares
135.49
Day Low
138.47
Day High
136.88
119.61
52 Week Low
145.61
52 Week High
136.88
2.84
Dividend in USD
2.06
Dividend Yield
18.33
P/E Ratio
99.51
Free Float in %
7.59
EPS in USD
56.82
Book Value per Share in USD
11.26
Cash Flow per Share in USD
Quest Diagnostics News More News
Historical Prices for Quest Diagnostics
| Date | Open | Close | Daily High | Daily Low |
|---|
Price change over selected period:
0%
0
Quest Diagnostics Analyst Data
Total Analysts: 31
Analyst: {{ANALYST_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}
Price
*Price Target
Lowest: 125.00
Median: 147.06
Highest: 165.00
*The average price target includes all analyst analysis, not just the most recent analysis presented in the chart.
Quest Diagnostics Analyst Opinions
- All
- Buy
- Hold
- Sell
| Date | Analyst | Rating | Price | |||
|---|---|---|---|---|---|---|
| 05/30/24 | J.P. Morgan | Maintained Hold | $155 | |||
| 04/25/24 | Barclays Capital | Maintained Hold | $144 | |||
| 04/24/24 | Citigroup Corp. | Maintained Hold | $145 | |||
| 04/24/24 | UBS | Maintained Hold | $146 | |||
| 04/24/24 | Mizuho | Maintained Buy | $155 | |||
| 02/07/24 | Jefferies & Company Inc. | Upgraded to Buy | $155 | |||
| 12/12/23 | Bank of America Merrill Lynch | Upgraded to Buy | $160 | |||
| 12/11/23 | Citigroup Corp. | Maintained Hold | $145 | |||
| 12/07/23 | UBS | Maintained Hold | $137 | |||
| 11/17/23 | J.P. Morgan | Maintained Hold | $149 | |||
| 11/06/23 | Piper Sandler | Maintained Hold | $140 | |||
| 10/25/23 | Citigroup Corp. | Maintained Hold | $130 | |||
| 10/16/23 | Piper Sandler | Maintained Hold | $130 | |||
| 08/03/23 | Morgan Stanley | Maintained Hold | $145 | |||
| 06/29/23 | Piper Sandler | Maintained Hold | $145 | |||
| 05/10/23 | Morgan Stanley | Maintained Hold | $145 | |||
| 05/02/23 | Bank of America Merrill Lynch | Downgraded to Hold | $148 | |||
| 04/03/23 | Citigroup Corp. | Upgraded to Hold | $142 | |||
| 03/17/23 | Mizuho | Maintained Buy | $165 | |||
| 02/03/23 | Wells Fargo & Co | Maintained Hold | $140 | |||
| 01/25/23 | Credit Suisse | Maintained Hold | $146 | |||
| 01/23/23 | Evercore | Maintained Hold | $159 | |||
| 01/12/23 | Baird Patrick & Co | Maintained Hold | $154 | |||
| 01/06/23 | Morgan Stanley | Maintained Hold | $158 | |||
| 12/14/22 | Mizuho | Maintained Buy | $165 | |||
| 11/17/22 | Citigroup Corp. | Downgraded to Sell | $125 | |||
| 10/21/22 | Morgan Stanley | Maintained Hold | $146 | |||
| 10/21/22 | Deutsche Bank | Maintained Hold | $140 | |||
| 08/22/22 | Morgan Stanley | Maintained Hold | $142 | |||
| 07/22/22 | Mizuho | Maintained Buy | $160 | |||
| 07/22/22 | Credit Suisse | Maintained Hold | $143 |
Quest Diagnostics Estimates* in USD
| 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|
| Revenue | 9,449 | 9,783 | 10,162 | 10,621 | 10,871 |
| Dividend | 2.90 | 3.00 | 3.06 | - | - |
| Dividend Yield (in %) | 2.12 % | 2.19 % | 2.23 % | - | - |
| EPS | 8.83 | 9.47 | 10.21 | 11.09 | 11.87 |
| P/E Ratio | 15.50 | 14.46 | 13.40 | 12.34 | 11.53 |
| EBIT | 1,489 | 1,565 | 1,675 | 1,798 | 1,979 |
| EBITDA | 1,901 | 2,019 | 2,144 | 2,252 | 2,369 |
| Net Profit | 943 | 1,012 | 1,087 | 1,235 | 1,330 |
| Net Profit Adjusted | 995 | 1,063 | 1,138 | 1,263 | 1,385 |
| Pre-Tax Profit | 1,297 | 1,386 | 1,499 | 1,668 | 1,822 |
| Net Profit (Adjusted) | 1,301 | 1,383 | 1,482 | - | - |
| EPS (Non-GAAP) ex. SOE | 8.83 | 9.47 | 10.21 | 11.09 | 11.87 |
| EPS (GAAP) | 7.86 | 8.51 | 9.33 | 10.00 | 10.97 |
| Gross Income | 3,145 | 3,277 | 3,416 | 3,600 | 3,761 |
| Cash Flow from Investing | -577 | -481 | -509 | -666 | -681 |
| Cash Flow from Operations | 1,296 | 1,467 | 1,581 | 1,598 | 1,710 |
| Cash Flow from Financing | -700 | -728 | -782 | -735 | -805 |
| Cash Flow per Share | 11.77 | 14.29 | 14.34 | - | - |
| Free Cash Flow | 876 | 1,036 | 1,141 | 1,132 | 1,230 |
| Free Cash Flow per Share | 7.73 | 9.20 | 9.99 | - | - |
| Book Value per Share | 61.41 | 66.67 | 72.42 | - | - |
| Net Debt | 4,006 | 3,425 | 3,082 | - | - |
| Research & Development Exp. | - | - | - | - | - |
| Capital Expenditure | 420 | 429 | 436 | 466 | 481 |
| Selling, General & Admin. Exp. | 1,583 | 1,613 | 1,721 | 1,744 | 1,783 |
| Shareholder’s Equity | 6,840 | 7,345 | 7,918 | 8,035 | 8,549 |
| Total Assets | 14,245 | 14,583 | 14,937 | 15,468 | 16,073 |
|
Previous Quarter ending 03/31/24 |
Current Quarter ending 06/30/24 |
Next Quarter ending 09/30/24 |
Current Year ending 12/31/24 |
Next Year ending 12/31/25 |
|
|---|---|---|---|---|---|
| Earnings Estimates | |||||
| No. of Analysts | 16 | 16 | 16 | 17 | 17 |
| Average Estimate | 1.856 USD | 2.333 USD | 2.307 USD | 8.830 USD | 9.465 USD |
| Year Ago | 1.795 USD | 2.089 USD | 1.991 USD | 7.589 USD | - |
| Publish Date | 4/23/2024 | 7/23/2024 | 10/22/2024 | - | - |
| Revenue Estimates | |||||
| No. of Analysts | 14 | 14 | 14 | 16 | 16 |
| Average Estimate | 2,287 USD | 2,392 USD | 2,363 USD | 9,449 USD | 9,783 USD |
| Year Ago | 2,331 USD | 2,338 USD | 2,295 USD | 9,252 USD | - |
| Publish Date | 4/23/2024 | 7/23/2024 | 10/22/2024 | - | - |
* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet
Income Statements in Mio. USD
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Sales | 9,252.00 | 9,883.00 | 10,788.00 | 9,437.00 | 7,726.00 | 7,531.00 | 7,709.00 |
| Change of sales in % | -6.38 | -8.39 | 14.32 | 22.15 | 2.59 | -2.31 | 2.58 |
| Gross profit on sales | 2,961.00 | 3,347.00 | 4,140.00 | 3,614.00 | 2,628.00 | 2,583.00 | 2,966.00 |
| Gross profit on sales change in % | -11.53 | -19.15 | 14.55 | 37.52 | 1.74 | -12.91 | 3.45 |
| Operating income | 1,351.00 | 1,622.00 | 2,444.00 | 2,105.00 | 1,220.00 | 1,224.00 | 1,283.00 |
| Operating income change in % | -16.71 | -33.63 | 16.10 | 72.54 | -0.33 | -4.60 | 4.39 |
| Income before tax | 1,130.00 | 1,235.00 | 2,599.00 | 1,884.00 | 1,076.00 | 926.00 | 1,030.00 |
| Income before tax change in % | -8.50 | -52.48 | 37.95 | 75.09 | 16.20 | -10.10 | -5.16 |
| Income after tax | 850.00 | 942.00 | 1,988.00 | 1,425.00 | 855.00 | 733.00 | 769.00 |
| Income after tax change in % | -9.77 | -52.62 | 39.51 | 66.67 | 16.64 | -4.68 | 19.78 |
Balance Sheet in Mio. USD
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Total liabilities | 7,604.00 | 6,830.00 | 7,049.00 | 7,135.00 | 7,080.00 | 5,659.00 | 5,468.00 |
| Long-term liabilities per share | 52.15 | 47.56 | 44.50 | 40.29 | 38.27 | 30.92 | 32.67 |
| Equity | 6,418.00 | 6,007.00 | 6,562.00 | 6,891.00 | 5,763.00 | 5,344.00 | 5,035.00 |
| Equity change in % | 7.03 | -8.55 | -4.66 | 19.82 | 8.15 | 5.99 | 6.33 |
| Balance sheet total | 14,022.00 | 12,837.00 | 13,611.00 | 14,026.00 | 12,843.00 | 11,003.00 | 10,503.00 |
| Balance sheet total change in % | 9.23 | -5.69 | -2.96 | 9.21 | 16.72 | 4.76 | 3.99 |
Key Data in USD
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Sales per share | 81.88 | 83.75 | 84.28 | 69.39 | 56.81 | 54.18 | 55.06 |
| P/E ratio (year end quote, basic EPS) | 18.33 | 19.60 | 11.14 | 11.33 | 16.99 | 15.79 | 17.93 |
| P/E ratio (ear end quote, diluted EPS) | 18.33 | 19.60 | 11.14 | 11.33 | 16.99 | 15.79 | 17.93 |
| P/E ratio (year end quote) | 18.33 | 19.60 | 11.14 | 11.33 | 16.99 | 15.79 | 17.93 |
| Dividend yield in % | 2.06 | 1.69 | 1.43 | 1.88 | 1.99 | 2.44 | 1.83 |
| Equity ratio in % | 44.98 | 45.91 | 47.34 | 48.19 | 43.92 | 47.41 | 46.85 |
| Debt ratio in % | 54.23 | 53.21 | 51.79 | 50.87 | 55.13 | 51.43 | 52.06 |
Quest Diagnostics Insider Activity
| Name | Date | shares traded | shares held | Price | type (sell/buy) | option |
|---|---|---|---|---|---|---|
| CARTER ROBERT B | 05/15/2024 | 1,482.00 | 1,482.00 | n/a | Buy | No |
| Doi Tracey | 05/15/2024 | 1,482.00 | 5,183.00 | n/a | Buy | No |
| RING TIMOTHY M | 05/15/2024 | 1,482.00 | 27,798.00 | n/a | Buy | No |
| PFEIFFER GARY M | 05/15/2024 | 1,482.00 | 28,916.00 | n/a | Buy | No |
| Lassiter Wright III | 05/15/2024 | 1,482.00 | 7,709.00 | n/a | Buy | No |
| MORRISON DENISE M | 05/15/2024 | 1,482.00 | 9,490.00 | n/a | Buy | No |
| Gregg Vicky B | 05/15/2024 | 1,482.00 | 17,892.00 | n/a | Buy | No |
| MAIN TIMOTHY L | 05/15/2024 | 1,482.00 | 25,094.00 | n/a | Buy | No |
| Diaz Luis | 05/15/2024 | 1,482.00 | 2,851.00 | n/a | Buy | No |
| KUPPUSAMY KARTHIK | 04/28/2024 | 1,760.00 | 13,435.00 | 140.00 | Sell | No |
| KUPPUSAMY KARTHIK | 04/21/2024 | 45.00 | 15,195.00 | 126.25 | Buy | No |
| SAMAD SAM | 04/21/2024 | 24.00 | 21,356.00 | 126.25 | Buy | No |
| Plewman Patrick | 04/21/2024 | 69.00 | 16,062.00 | 126.25 | Buy | No |
| Gregg Vicky B | 04/21/2024 | 81.00 | 16,410.00 | 126.24 | Buy | No |
| Plewman Patrick | 03/25/2024 | 114.00 | 15,981.00 | 128.11 | Sell | No |
| DELANEY MARK E | 03/25/2024 | 170.00 | 5,433.00 | 128.11 | Sell | No |
| PREVOZNIK MICHAEL E | 02/28/2024 | 5,611.00 | 38,478.00 | 125.88 | Sell | No |
| PREVOZNIK MICHAEL E | 02/27/2024 | 456.00 | 44,089.00 | 126.36 | Sell | No |
| PREVOZNIK MICHAEL E | 02/27/2024 | 405.00 | 44,545.00 | 126.36 | Sell | No |
| KUPPUSAMY KARTHIK | 02/27/2024 | 68.00 | 15,124.00 | 126.36 | Sell | No |
| KUPPUSAMY KARTHIK | 02/27/2024 | 205.00 | 15,192.00 | 126.36 | Sell | No |
| GARDNER MARK A | 02/27/2024 | 262.00 | 4,793.00 | 126.36 | Sell | No |
| DEPPE MICHAEL J | 02/27/2024 | 57.00 | 34,930.00 | 126.36 | Sell | No |
| DEPPE MICHAEL J | 02/27/2024 | 52.00 | 34,987.00 | 126.36 | Sell | No |
| Davis J. E. | 02/27/2024 | 1,804.00 | 125,968.00 | 126.36 | Sell | No |
Quest Diagnostics Dividend Calendar
| Date | Name | Dividend | *yield | Currency |
|---|---|---|---|---|
| 2023 | Quest Diagnostics Inc. | 2.84 | 2.06 | USD |
| 2022 | Quest Diagnostics Inc. | 2.64 | 1.69 | USD |
| 2021 | Quest Diagnostics Inc. | 2.48 | 1.43 | USD |
| 2020 | Quest Diagnostics Inc. | 2.24 | 1.88 | USD |
| 2019 | Quest Diagnostics Inc. | 2.12 | 1.99 | USD |
| 2018 | Quest Diagnostics Inc. | 2.03 | 2.44 | USD |
| 2017 | Quest Diagnostics Inc. | 1.80 | 1.83 | USD |
| 2016 | Quest Diagnostics Inc. | 1.65 | 1.80 | USD |
| 2015 | Quest Diagnostics Inc. | 1.52 | 2.14 | USD |
| 2014 | Quest Diagnostics Inc. | 1.32 | 1.97 | USD |
| 2013 | Quest Diagnostics Inc. | 1.20 | 2.24 | USD |
| 2012 | Quest Diagnostics Inc. | 0.81 | 1.39 | USD |
| 2011 | Quest Diagnostics Inc. | 0.47 | 0.81 | USD |
| 2010 | Quest Diagnostics Inc. | 0.40 | 0.74 | USD |
| 2009 | Quest Diagnostics Inc. | 0.40 | 0.66 | USD |
| 2008 | Quest Diagnostics Inc. | 0.40 | 0.77 | USD |
| 2007 | Quest Diagnostics Inc. | 0.40 | 0.76 | USD |
| 2006 | Quest Diagnostics Inc. | 0.40 | 0.75 | USD |
| 2005 | Quest Diagnostics Inc. | 0.36 | 0.70 | USD |
| 2004 | Quest Diagnostics Inc. | 0.30 | 0.63 | USD |
| 2003 | Quest Diagnostics Inc. | 0.08 | 0.22 | USD |
| 2002 | Quest Diagnostics Inc. | 0.00 | 0.00 | USD |
| 2001 | Quest Diagnostics Inc. | 0.00 | 0.00 | USD |
| 2000 | Quest Diagnostics Inc. | 0.00 | 0.00 | USD |
| 1999 | Quest Diagnostics Inc. | 0.00 | 0.00 | USD |
*Yield of the Respective Date
Quest Diagnostics Inc. Calendar
| Event | Estimate | Info | Date |
|---|---|---|---|
| Earnings Report | 2.333 USD | Q2 2024 Earnings Release | 07/23/2024 |
| Earnings Report | 2.307 USD | Q3 2024 Earnings Release | 10/22/2024 |
| Earnings Report | 2.141 USD | Q4 2024 Earnings Release | 01/30/2025 |
| Earnings Report | 2.187 USD | Q1 2025 Earnings Release | 04/29/2025 |
| Earnings Report | 2.499 USD | Q2 2025 Earnings Release | 07/29/2025 |
Quest Diagnostics Inc. Past Events
| Event | Actual EPS | Info | Date |
|---|---|---|---|
| Annual General Meeting | - | Annual General Meeting | 05/16/2024 |
| Earnings Report | 1.739 USD | Q1 2024 Earnings Release | 04/23/2024 |
| Press Conference | - | - | 04/23/2024 |
| Press Conference | - | - | 02/01/2024 |
| Press Conference | - | - | 10/24/2023 |
| Press Conference | - | - | 07/26/2023 |
Quest Diagnostics Profile
Quest Diagnostics, Inc. engages in the provision of diagnostic testing, information and services. It operates through the Diagnostic Information Services (DIS) and All Other segments. The DIS segment offers diagnostic information services to patients, clinicians, hospitals, health plans, and employers. The All Other segment consists of risk assessment services, healthcare information technology, diagnostic products, and clinical trials testing businesses. The company was founded in 1967 and is headquartered in Secaucus, NJ.
Moody’s Daily Credit Risk Score
Quest Diagnostics Shareholder
| Owner | in % |
|---|---|
| Freefloat | 99.51 |
| The Vanguard Group, Inc. | 12.22 |
| Vanguard Group, Inc. (Subfiler) | 12.08 |
| SSgA Funds Management, Inc. | 4.82 |
| State Street Corp. | 4.68 |
| BlackRock Fund Advisors | 3.72 |
| Victory Capital Management, Inc. (Investment Management) | 3.53 |
| American Century Cos., Inc. | 3.49 |
| Vanguard Total Stock Market ETF | 3.15 |
| Vanguard 500 Index Fund | 2.56 |
| BlackRock Institutional Trust Co. NA | 2.38 |
| Wellington Management Co. LLP | 2.35 |
| Victory Sycamore Established Value Fund | 2.34 |
| Geode Capital Management LLC | 2.28 |
| Vanguard Mid Cap Index Fund | 2.16 |
Shareholder percentage totals can add to more than 100% because some holders are included in the free float.
Quest Diagnostics Management
| Name | Job |
|---|---|
| James E. Davis | Chairman, President & Chief Executive Officer |
| Michael Joseph Deppe | Chief Accounting Officer, SVP & Controller |
| Mark E. Delaney | Chief Commercial Officer & Senior Vice President |
| Kristin Wallace | Chief Compliance Officer & Senior Vice President |
| Sam A. Samad | Chief Financial Officer & Executive Vice President |
| Cecilia K. McKenney | Chief Human Resources Officer & Senior VP |
| Yuri A. Fesko | Chief Medical Officer & Senior Vice President |
| Alyssa Waxenberg | Director-Digital Products & Consumer Marketing |
| Doug Lang | Director-Technical Products |
| Vicky B. Gregg | Independent Director |
| Denise M. Morrison | Independent Director |
| Luis A. Diaz | Independent Director |
| Robert B. Carter | Independent Director |
| Wright L. Lassiter | Independent Director |
| Gary M. Pfeiffer | Independent Director |
| Tracey C. Doi | Independent Director |
| Timothy L. Main | Independent Director |
| Timothy M. Ring | Lead Independent Director |
| Sean D. Mersten | Secretary & Vice President |
| Murali Balakumar | Senior VP, Chief Information & Digital Officer |
| Michael E. Prevoznik | Senior Vice President & General Counsel |
| Karthik Kuppusamy | Senior Vice President-Clinical Solutions |
| Patrick Plewman | Senior Vice President-Diagnostic Services |
| Catherine T. Doherty | Senior Vice President-Regional Businesses |
| Dermot Victor Shorten | Senior Vice President-Ventures, Strategy, M&A |
| Tracy L. Cinco-Abela | Treasurer & Vice President |
| Shawn Bevec | Vice President-Investor Relations |